about
Vitamin D and rheumatic diseasesThe Association between Weight Gain/Restoration and Bone Mineral Density in Adolescents with Anorexia Nervosa: A Systematic ReviewSite-specific effects of strength training on bone structure and geometry of ultradistal radius in postmenopausal women.Capacitively coupled electric field for pain relief in patients with vertebral fractures and chronic pain.The volumetric bone density and cortical thickness in adult patients affected by osteogenesis imperfecta.Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study.Neridronic acid for the treatment of bone metabolic diseases.Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.Allergy and the bone: unexpected relationships.Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis.Osteoporosis treatment: why ibandronic acid?Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.Insight into the WNT system and its drug related response.Bone involvement and osteoporosis in mastocytosis.Focal bone involvement in inflammatory arthritis: the role of IL17.Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?Relationship between body composition and both cardiovascular risk factors and lung function in systemic sclerosis.The use of bisphosphonates in women: when to use and when to stop.Safety issues and adverse reactions with osteoporosis management.Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.Management of patients with complex regional pain syndrome type I.Prednisone compared to methylprednisolone in the polymyalgia rheumatica treatment.Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial.Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Rheumatoid Arthritis without Overt Cardiac Disease.Prevalence and Factors Associated with Subclinical Left Ventricular Systolic Dysfunction Evaluated by Mid-Wall Mechanics in Rheumatoid Arthritis.Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.Prevalence and factors related to left ventricular systolic dysfunction in asymptomatic patients with rheumatoid arthritis. A prospective tissue Doppler echocardiography study.Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis.Prevalence and factors related to inappropriately high left ventricular mass in patients with rheumatoid arthritis without overt cardiac disease.DXA bone mineral density in males: retrospective study in real life.Strong relationship between vitamin D status and bone mineral density in anorexia nervosa.Bisphosphonates vs infliximab in ankylosing spondylitis treatment.Bone anabolic agents: the unanswered queries.Higher circulating parathormone is associated with smaller and weaker bones in obese children.Acute phase response after zoledronic acid is associated with long-term effects on white blood cells.Intramuscular neridronate in postmenopausal women with low bone mineral density.Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight.Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children.Computed radiographic absorptiometry and morphometry in the assessment of postmenopausal bone loss.
P50
Q27015017-EA3F6E9F-750E-4CF5-A0CE-FFE64B94499AQ28075579-E6509344-B8DE-44B4-AEAA-27BFBE816D38Q31931957-82E96DE4-89B7-4756-8718-8A11D81C4104Q33631277-277FA145-4530-4948-B56D-7B2386D1EB7FQ33966432-8BB6F022-E13D-4141-A1DB-4813F6153A3CQ34315007-A196BF02-D8A7-4A68-AC6F-8280FA2A5978Q35003623-C44C2CCA-5685-4D81-8022-AB7B2CCF3B14Q37583127-69F2BC52-D984-4407-A88C-3607D2CE450AQ37923545-F223F6B5-6B86-475D-89DA-B19DB5751FB8Q38102040-F95810D1-7F02-4968-9073-589D0465EBA1Q38104738-F716D996-88D4-4609-BECB-66AB89E13E2EQ38113112-BBFB82FE-B1EA-432C-801E-D3AA89F8FA17Q38176545-A115E35B-B328-42C3-A32D-E10D595134D8Q38205506-46811D4B-549B-4555-A211-F503802FBBCDQ38295616-7092441D-252F-4F64-B638-B780DC79023FQ38343436-7A42D199-479D-42B7-B4D3-DB5FA3CB201EQ38398582-6E8D3BA2-E7F6-437C-B271-CCD2F7610621Q38446736-D5F17E37-8549-4628-8633-5574006ED7A6Q38584336-D238D706-53A5-4265-8DA9-ADE9DF18B139Q38677822-548FDB29-392F-4029-BB64-F494850A02D1Q38739710-F0FC598E-80BF-4FBF-84AC-C70C42DCC608Q38755588-197A3361-8F9A-49BE-B544-09A11A613C13Q39202161-EC190202-CC05-4329-8B96-C7082389CC5EQ39203039-C8F5E4AA-677C-4112-80BF-45A7537CC21EQ39963413-4D00DC24-82A9-4363-8A5F-C385474A7F6DQ39985617-0DFD919A-D806-4BCD-8F1A-4CEECBBC0E68Q40310722-FAC76327-C45C-4D37-9DD1-082FC64E2548Q40922691-735E057A-F61C-4C59-B40A-628CBA7F965DQ41067642-A1958B76-CD8A-472A-AA94-B8125BCFCB29Q41519417-E62FE730-6FF7-4F10-8DFB-FABDECF6FB94Q41726250-30856C28-2490-4F8A-9EB2-8663C9F72D8DQ41734476-AACCE1FB-6DCB-46DB-BA4B-539B243AEC46Q44230212-791570A0-4335-4397-AAB5-36156BDFE0EDQ44959758-17C90D82-FB66-4083-8485-853E16400018Q45340912-5119D436-DC53-4B50-AE8D-AA3869023DFCQ45731159-ACF2CEC2-DAEA-4AA6-8328-F8C1913A7A7BQ46301232-452178EC-1192-4D58-A905-12A6C106B910Q47304893-A228A55B-6D87-4931-911D-7AA2685B7BCDQ47348574-4B6399F0-C003-4EC4-9281-E20573497A21Q48523641-7E8AEFC1-5705-4711-A70F-C922C60D7996
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-7471-3076
@en
name
davide gatti
@ast
davide gatti
@en
davide gatti
@es
davide gatti
@nl
type
label
davide gatti
@ast
davide gatti
@en
davide gatti
@es
davide gatti
@nl
prefLabel
davide gatti
@ast
davide gatti
@en
davide gatti
@es
davide gatti
@nl
P106
P1153
7007102867
P31
P496
0000-0002-7471-3076